Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 59

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 59
---
, consultants, advisors and any other third parties who have access to our proprietary know-how, information, or technology.
With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations.
We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or
proprietary technology and processes. We cannot be certain that our trade secrets and other confidential proprietary information will
not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information,
including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition,
some courts inside and outside the United States are less willing or unwilling to protect trade secrets.

We may need to share our proprietary
information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened
risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or
controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor
or other third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our
trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would
be harmed.

In addition, we take other
appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology
by third parties. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached,
and we may not have adequate remedies for any breach. We have also adopted policies and conduct training that provides guidance on our
expectations, and our advice for best practices, in protecting our trade secrets. Despite these undertakings, we may not be able to effectively
protect our trade secrets.

We may not identify relevant third-party
patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability
to develop and market our products.

The intellectual property
landscape around our radiotherapeutic product candidates is crowded, rapidly evolving and interdisciplinary,